<DOC>
	<DOCNO>NCT00161902</DOCNO>
	<brief_summary>The purpose study monitor safety FS VH S/D evaluate whether FS VH S/D superior standard treatment reduce blood loss subject undergoing total hip replacement cement-free hip prosthesis .</brief_summary>
	<brief_title>Efficacy Safety Fibrin Sealant Vapor Heated Solvent/Detergent Treated ( FS VH S/D ) Hemostasis Subjects Undergoing Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Each subject include study must fulfill follow inclusion criterion : Subjects receive cement free hip prosthesis due coxarthrosis primary dysplastic arthrosis grade 1 â€“ 3 accord Crowe rheumatoid arthritis well subject receive cement free hip prosthesis due femur head necrosis ( Crowe classification ) . ASA NSAIDs discontinue one week prior surgery Written inform consent Male female least 19 year age Subjects fulfil follow exclusion criterion recruit study : Impaired coagulation Previous hip surgery Acetabular roof plastic Known hypersensitivity aprotinin component product Immunodeficiency Increased red cell production Pregnant lactate woman ( positive urine serum pregnancy test ; test require female subject post menopausal surgically sterilize ) . Subjects concurrently participate another clinical trial receive another investigational drug within last 30 day . Also patient abnormal coagulation value due anticoagulant like coumadin heparin must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Arthroplasty</keyword>
	<keyword>Hip Prosthesis</keyword>
	<keyword>Cement Free Hip Prosthesis</keyword>
	<keyword>Femur Head Necrosis</keyword>
	<keyword>Coxarthrosis</keyword>
</DOC>